FDA Approves IND for mRNA Vaccine for Epstein-Barr Virus-Related Cancer
WGc-043 is the first and only vaccine approved for this use.
Editor's note: An earlier version of this story incorrectly stated that the FDA had approved WGc-043. The FDA has approved the Investigational New Drug (IND) application for the vaccine.
The FDA has approved the IND for WGc-043, the first and only Epstein-Barr virus-related mRNA cancer vaccine.1
This approval “represents a significant advance in cancer treatment, offering new hope to patients with advanced [Epstein-Barr virus-related cancers,” noted a company press release.1 Epstein-Barr virus, a type of herpes virus that causes infectious mononucleosis, increases an individual’s risk of developing several types of cancers, including nasopharyngeal cancer, natural killer T-cell lymphoma, esophageal cancer, breast cancer, cervical cancer, and stomach cancer. It is also associated with autoimmune conditions such as multiple sclerosis and systemic lupus erythematosus.2
Approximately 90% of Americans are infected with Epstein-Barr virus by age 35. | image credit: Dr_Microbe - stock.adobe.com
READ MORE: HPV Vaccines Have Reshaped the Epidemiological Landscape
The vaccine has demonstrated positive efficacy, low toxicity, and broad applicability; it has also been shown to be cost effective. Investigator-initiated trials of the WGc-043 vaccine in nasopharyngeal cancer and natural killer T-cell lymphoma showed “superior safety and efficacy compared to other publicly available mRNA therapeutic cancer vaccines.”1
Epstein-Barr infection is lifelong, although symptoms typically abate after the first few weeks. The virus infects B lymphocites and stays present in these cells. Approximately 90% of people in the US are infected with Epstein-Barr virus by age 35.1,3
Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.
Currently, there are no treatments or preventive vaccines for Epstien-Barr virus. However, Moderna is currently investigating mRNA-1189, an mRNA vaccine for Epistein-Barr virus.3 The phase 1 Eclipse clinical trial (NCT05164049) is specifically evaluating the safety and immune response of this vaccine. Participants include healthy volunteers aged 12 to 30 years who will receive 3 injections of either mRNA-1189 or placebo. The trial is anticipated to continue through June 2025.
READ MORE: Immunization Resource Center
References
WestGene’s mRNA therapeutic cancer vaccine receives FDA approval. News release. WestGene. May 10, 2024. Accessed May 10, 2024. https://www.prnewswire.com/news-releases/westgenes-mrna-therapeutic-cancer-vaccine-receives-fda-approval-302142067.html
Serani S. FDA approves Epstein-Barr mRNA cancer vaccine WGc-043. Targeted Oncology. May 10, 2024. Accessed May 10, 2024. https://www.targetedonc.com/view/fda-approves-epstein-barr-mrna-cancer-vaccine-wgc-043
A clinical trial of an Epstein-Barr virus (EBV) vaccine in young adults. Moderna. Accessed May 10, 2024. https://trials.modernatx.com/study/?id=mRNA-1189-P101
